Aptar Pharma has announced the appointment of Jean-Marc Pardonge as President of Aptar Pharma’s Prescription Division, succeeding Salim Haffar, and as General Manager of Aptar Stelmi. Aptar's prescription division develops and manufactures a range of nasal and pulmonary delivery devices. Pardonge has worked in the prescription division since 2000, first as R&D … [Read more...] about Aptar Pharma appoints Jean-Marc Pardonge President of prescription division
News
Marinomed gets Chinese patent for polymer used in anti-viral nasal spray
Vienna, Austria-based Marinomed has announced the granting of Chinese patent No. CN101678040, titled "Antiviral Polymer," for a component of its Mavirex technology platform. According to the company, the patent covers prevention and treatment of the common cold using the polymer. Marinomed's Coldamaris nasal spray for the common cold is sold over the counter in … [Read more...] about Marinomed gets Chinese patent for polymer used in anti-viral nasal spray
Copley launches pump for high flow rate cascade impaction
Copley Scientific has officially launched the SCP5 Super Capacity Pump which is capable of generating flow rates as high as 100 L/min for cascade impaction of dry powder inhalers. The new model, a 1.5 kW oil-lubricated rotary vane pump, allows labs to use a single pump for DPI testing instead of having to use two smaller pumps to generate the required flow. … [Read more...] about Copley launches pump for high flow rate cascade impaction
OptiNose announces Phase 3 data, grant
OptiNose has announced Phase 3 results from a study of its sumatriptan nasal powder for the treatment of migraine, as well as a grant from the Research Council of Norway to study nasal delivery of oxytocin for the treatment of autism spectrum disorders. According to OptiNose US, the Phase 3 TARGET study found that 42% of patients with moderate to severe migraines … [Read more...] about OptiNose announces Phase 3 data, grant
Pearl Therapeutics gets funding for Phase 3 studies of PT003
Pearl Therapeutics has raised $65 million from current investors to enable initiation of Phase 3 trials for its PT003 glycopyrrolate (GP)/formoterol fumarate (FF) MDI for the treatment of COPD, the company says. This round of financing brings the total to $167.5 million since 2007. Pearl CEO Chuck Bramlage said, “Through our comprehensive Phase 2 program, Pearl … [Read more...] about Pearl Therapeutics gets funding for Phase 3 studies of PT003
Savara’s AeroVanc gets orphan drug designation in US
According to Savara Pharmaceuticals, the company's AeroVanc inhaled vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in cystic fibrosis patients has been granted orphan drug status by the FDA. Aerovanc inhalation powder, which is delivered using a capsule-based DPI, has completed Phase 1 trials, and Savara says that it is … [Read more...] about Savara’s AeroVanc gets orphan drug designation in US
Novartis files application for QVA149 in Japan
QVA149 developers Vectura and Sosei have confirmed that Novartis has submitted an application for Japanese approval of the inhaled fixed dose combination of indacaterol maleate and glycopyrronium bromide for the treatment of COPD. Novartis, which licensed the DPI from the two companies, also recently submitted an application for the product in Europe. Japan … [Read more...] about Novartis files application for QVA149 in Japan
Boehringer Ingelheim to double production at Respimat facility
Boehringer Ingelheim has announced an €85 million expansion to the BI microParts GmbH inhaler manufacturing facililty in Dortmund, Germany meant to double its annual production of Respimat inhalers to 44 million by 2015. Filling of the Respimat inhalers takes place in Ingelheim. The company says that it will need to add more than 100 new hires to the existing 450 … [Read more...] about Boehringer Ingelheim to double production at Respimat facility
FDA issues warning on ingestion of nasal sprays
The FDA has issued a warning to parents and health care professionals after receiving reports of accidental ingestion of nasal sprays and eye drops by children. According to the agency, the decongestant nasal sprays reported to have sickened children 5 years and younger who swallowed them had the active ingredients tetrahydrozoline or oxymetazoline. The warning … [Read more...] about FDA issues warning on ingestion of nasal sprays
Team Consulting, Lab Automate win awards
Two companies that provide services to OINDP developers and manufacturers have been awarded major prizes recently. The 2012 British Engineering Excellence Awards recognized device design experts Team Consulting as "Consultancy of the Year." Criteria for the award include, "the speed with which projects have been delivered," "the range of technologies handled by the … [Read more...] about Team Consulting, Lab Automate win awards